Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Psychiatry and Mental Health
- Pediatrics
- Physical Medicine & Rehabilitation
- Nutrition and Food Science
- Molecular Biology
- Anatomy
- Transplantation Medicine
- Diabetology
Abstract
Citation: Ann Clin Case Rep. 2022;7(1):2361.DOI: 10.25107/2474-1655.2361
Liquid Biopsy for Detection of T790M Mutation in Patient with EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Case Report
Derasse M1*, D’Haene N2, Berghmans T1 and Grigoriu B1
1Department of Thoracic Oncology, Jules Bordet Institute, Belgium
2Department of Pathology, Erasme Hospital, Belgium
*Correspondance to: Marion Derasse
PDF Full Text Case Report | Open Access
Abstract:
Introduction: Liquid biopsy is increasingly used in management of Non-Small Cell Lung Cancer (NSCLC), especially when tissue availability tumor is limited. This especially true in the context of Leptomeningeal metastases. The circulating cell-free DNA from plasma or cerebrospinal fluid may provide genetic material needed for the diagnosis and management of patients with LM progression. Case Report: We present the case of a 38-year-old Chinese female with a stage IVb NSCLC Epidermal Growth Factor Receptor (EGFR)- mutant with LM progression under Afatinib. A Droplet Digital PCR showed the presence of an EGFR exon 19 deletion and the T790M resistance mutation on both on plasma and CSF. Osimertinib resulted a rapid improvement in the clinical and neurological condition. Conclusion: Analysis of cfDNA can provide valuable data for management of EGFR-mutant NSCLC progression under tyrosine kinase inhibitors.
Keywords:
Cite the Article:
Derasse M, D’Haene N, Berghmans T, Grigoriu B. Liquid Biopsy for Detection of T790M Mutation in Patient with EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Case Report. Ann Clin Case Rep. 2022; 7: 2361.